Related Experiment Video
Updated: Apr 5, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Safety, immunogenicity and infectivity of new live attenuated influenza vaccines
Irina Isakova-Sivak1, Larisa Rudenko
1a Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg, Russia.
Abstract:
Live attenuated influenza vaccines (LAIVs) are believed to be immunologically superior to inactivated influenza vaccines, because they can induce a variety of adaptive immune responses, including serum antibodies, mucosal and cell-mediated immunity. In addition to the licensed cold-adapted LAIV backbones, a number of alternative LAIV approaches are currently being developed and evaluated in preclinical and clinical studies. This review summarizes recent progress in the development and evaluation of LAIVs, with special attention to their safety, immunogenicity and infectivity for humans, and discusses their perspectives for the future.
Related Concept Videos
Vaccinations
Influenza
Vaccines
Leaky Scanning

